MA29774B1 - Utilisation de derives azabicyclo - Google Patents
Utilisation de derives azabicycloInfo
- Publication number
- MA29774B1 MA29774B1 MA30740A MA30740A MA29774B1 MA 29774 B1 MA29774 B1 MA 29774B1 MA 30740 A MA30740 A MA 30740A MA 30740 A MA30740 A MA 30740A MA 29774 B1 MA29774 B1 MA 29774B1
- Authority
- MA
- Morocco
- Prior art keywords
- disorder
- azabicyclo derivatives
- nervosa
- hyperchondriasis
- sydeham
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal Substances (AREA)
Abstract
Utilisation de dérivés d'azabicyclohexane La présente invention propose une utilisation nouvelle d'un composé de formule (I) ou d'un de ses sels ou produits de solvatation pharmaceutiquement acceptables, formule dans laquelle G est choisi dans un groupe consistant en des groupes : phényle, pyridyle, benzothiazolyle, indazolyle ; p représente un nombre entier de 0 à 5 ; R1 est choisi indépendamment dans un groupe consistant en des groupes : halogéno, hydroxyle, cyano, alkyle en C1 à C4, halogénalkyle en C1 à C4, alkoxy en C1 à C4, halogénalkoxy en C1 à C4, alcanoyle en C1 à C4 ; ou bien correspond à un groupe R5 ; R2 représente un atome d'hydrogène ou un groupe alkyle en C1 à C4 ; R3 représente un groupe alkyle en C1 à C4 ; R4 représente un atome d'hydrogène ou un groupe phényle, un groupe hétérocyclyle, un groupe hétéroaromatique penta- ou hexagonal, ou un groupe bicyclique octo- à undécagonal, n'importe lequel de ces groupes étant facultativement substitué avec 1, 2, 3 ou 4 substituants choisis dans le groupe consistant en des substituants : halogéno, cyano, alkyle en C1 à C4, halogénalkyle en C1 à C4, alkoxy en C1 à C4, alcanoyle en C1 à C4 ; R5 représente un groupement choisi dans le groupe consistant en des groupements : isoxazolyle, -CH2-N-pyrrolyle, 1,l-dioxido-2-isothiazolidinyle, thiényle, thiazolyle, pyridyle, 2-pyrrolidinonyle ; un tel groupe étant facultativement substitué avec un ou deux substituants choisis entre des substituants : halogéno, cyano, alkyle en C1 à C4, halogénalkyle en C1 à C4, alkoxy en C1 à C4, alcanoyle en C1 à C4 ; et, lorsque R1 représente un atome de chlore et p est égal à 1, un tel groupe R1 n'est pas présent en position ortho par rapport à la liaison de réunion au reste de la molécule ; et, lorsque R1 correspond à R5, p est égal à 1 ; dans la production d'un médicament destiné au traitement d'un trouble somatoforme tel que le trouble dysmorphique corporel ou l'hyperchondrie, la boulimie mentale, l'anorexie mentale, la consommation excessive de nourriture, la paraphilie et des addictions sexuelles non paraphiliques, la chorée de Sydeham, les torticolis, l'autisme, d'un trouble du mouvement comprenant le syndrome de Tourette ; et dans la production d'un médicament destiné au traitement de l'éjaculation précoce.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0517193.9A GB0517193D0 (en) | 2005-08-22 | 2005-08-22 | Novel use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29774B1 true MA29774B1 (fr) | 2008-09-01 |
Family
ID=35098098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30740A MA29774B1 (fr) | 2005-08-22 | 2008-03-11 | Utilisation de derives azabicyclo |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20090036461A1 (fr) |
| EP (1) | EP1917013B1 (fr) |
| JP (1) | JP5166267B2 (fr) |
| KR (1) | KR101363090B1 (fr) |
| CN (1) | CN101291669B (fr) |
| AT (1) | ATE500826T1 (fr) |
| AU (1) | AU2006284077B2 (fr) |
| BR (1) | BRPI0614929A2 (fr) |
| CA (1) | CA2620090A1 (fr) |
| CR (1) | CR9807A (fr) |
| DE (1) | DE602006020589D1 (fr) |
| EA (1) | EA016084B1 (fr) |
| ES (1) | ES2361933T3 (fr) |
| GB (1) | GB0517193D0 (fr) |
| IL (1) | IL189435A0 (fr) |
| MA (1) | MA29774B1 (fr) |
| MX (1) | MX2008002564A (fr) |
| NO (1) | NO20081314L (fr) |
| WO (1) | WO2007022980A1 (fr) |
| ZA (1) | ZA200801352B (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1745040E (pt) * | 2004-02-23 | 2010-03-08 | Glaxo Group Ltd | Derivados do azabiciclo3.1.0-hexano úteis como moduladores dos receptores d3 da dopamina |
| US20070043100A1 (en) | 2005-08-16 | 2007-02-22 | Hagen Eric J | Novel polymorphs of azabicyclohexane |
| GB0507601D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507602D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0512099D0 (en) * | 2005-06-14 | 2005-07-20 | Glaxo Group Ltd | Compounds |
| EP1891056B1 (fr) * | 2005-06-14 | 2010-10-13 | Glaxo Group Limited | Nouveaux composés |
| EP1915146A4 (fr) | 2005-07-27 | 2010-06-02 | Dov Pharmaceutical Inc | Nouveaux 1-aryl-3-azabicyclo[3.1.0]hexanes : synthèse et emploi dans le traitement des troubles neuropsychiatriques |
| GB0517191D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| US7799815B2 (en) * | 2005-08-22 | 2010-09-21 | Glaxo Group Limited | Triazole derivatives as modulators of dopamine D3 receptors |
| GB0517187D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517175D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0607899D0 (en) | 2006-04-03 | 2006-05-31 | Glaxo Group Ltd | Process for preparing heterocyclic derivatives |
| EP2007751B1 (fr) * | 2006-04-03 | 2013-08-21 | Glaxo Group Limited | Dérivés d'azabicyclo [3. 1. 0] hexyle utilisés comme modulateurs des récepteurs de la dopamine d3 |
| WO2007113258A1 (fr) * | 2006-04-03 | 2007-10-11 | Glaxo Group Limited | Dérivés d'azabicyclo [3. 1. o] hexane utilisés comme modulateurs des récepteurs de la dopamine d3 |
| US20080045725A1 (en) | 2006-04-28 | 2008-02-21 | Murry Jerry A | Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane |
| GB0616574D0 (en) * | 2006-08-21 | 2006-09-27 | Glaxo Group Ltd | Compounds |
| US8138377B2 (en) | 2006-11-07 | 2012-03-20 | Dov Pharmaceutical, Inc. | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use |
| EP2167083B1 (fr) * | 2007-06-06 | 2015-10-28 | Euthymics Bioscience, Inc. | 1- hétéroaryl-3-azabicyclo[3.1.0]hexanes, leurs méthodes de préparation et leur utilisation comme médicaments |
| US9133159B2 (en) * | 2007-06-06 | 2015-09-15 | Neurovance, Inc. | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
| KR20120106697A (ko) * | 2009-06-26 | 2012-09-26 | 파나세아 바이오테크 리미티드 | 신규 아자비시클로헥산 |
| WO2012033956A1 (fr) | 2010-09-08 | 2012-03-15 | Mithridion, Inc. | Composés et compositions améliorant la cognition, méthodes de préparation et méthodes de traitement |
| US20140206740A1 (en) | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| US9314600B2 (en) | 2012-04-15 | 2016-04-19 | Bioconnect Systems, Inc. | Delivery system for implantable flow connector |
| US11447484B2 (en) | 2018-01-26 | 2022-09-20 | Shionogi & Co., Ltd. | Cyclic compound having dopamine D3 receptor antagonistic effect |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI244481B (en) | 1998-12-23 | 2005-12-01 | Pfizer | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| US20020103198A1 (en) * | 2000-12-04 | 2002-08-01 | Fliri Anton F.J | Acylamino cyclopropane derivatives |
| PT1745040E (pt) * | 2004-02-23 | 2010-03-08 | Glaxo Group Ltd | Derivados do azabiciclo3.1.0-hexano úteis como moduladores dos receptores d3 da dopamina |
| SE526837C2 (sv) * | 2004-02-24 | 2005-11-08 | Kongsberg Automotive Asa | Växelspakstransmission |
| BRPI0518823A2 (pt) * | 2004-12-02 | 2008-12-09 | Abbott Gmbh & Co Kg | compostos de triazol adequados para o tratamento de transtornos que respondam À modulaÇço do receptor d3 da dopamina |
| GB0507601D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507602D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507680D0 (en) * | 2005-04-15 | 2005-05-25 | Glaxo Group Ltd | Compounds |
| EP1891056B1 (fr) * | 2005-06-14 | 2010-10-13 | Glaxo Group Limited | Nouveaux composés |
| GB0512099D0 (en) * | 2005-06-14 | 2005-07-20 | Glaxo Group Ltd | Compounds |
| GB0517191D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517187D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517175D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| US7799815B2 (en) * | 2005-08-22 | 2010-09-21 | Glaxo Group Limited | Triazole derivatives as modulators of dopamine D3 receptors |
| EA200870404A1 (ru) * | 2006-04-03 | 2009-04-28 | Глэксо Груп Лимитед | Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3 |
| GB0616574D0 (en) * | 2006-08-21 | 2006-09-27 | Glaxo Group Ltd | Compounds |
-
2005
- 2005-08-22 GB GBGB0517193.9A patent/GB0517193D0/en not_active Ceased
-
2006
- 2006-08-21 EA EA200800655A patent/EA016084B1/ru not_active IP Right Cessation
- 2006-08-21 BR BRPI0614929-4A patent/BRPI0614929A2/pt not_active IP Right Cessation
- 2006-08-21 JP JP2008527394A patent/JP5166267B2/ja not_active Expired - Fee Related
- 2006-08-21 AU AU2006284077A patent/AU2006284077B2/en not_active Ceased
- 2006-08-21 WO PCT/EP2006/008314 patent/WO2007022980A1/fr not_active Ceased
- 2006-08-21 DE DE602006020589T patent/DE602006020589D1/de active Active
- 2006-08-21 US US12/064,119 patent/US20090036461A1/en not_active Abandoned
- 2006-08-21 CN CN2006800389371A patent/CN101291669B/zh not_active Expired - Fee Related
- 2006-08-21 CA CA002620090A patent/CA2620090A1/fr not_active Abandoned
- 2006-08-21 MX MX2008002564A patent/MX2008002564A/es active IP Right Grant
- 2006-08-21 ES ES06777058T patent/ES2361933T3/es active Active
- 2006-08-21 AT AT06777058T patent/ATE500826T1/de not_active IP Right Cessation
- 2006-08-21 EP EP06777058A patent/EP1917013B1/fr active Active
- 2006-08-21 KR KR1020087006993A patent/KR101363090B1/ko not_active Expired - Fee Related
-
2008
- 2008-02-08 ZA ZA2008/01352A patent/ZA200801352B/en unknown
- 2008-02-11 IL IL189435A patent/IL189435A0/en unknown
- 2008-03-11 MA MA30740A patent/MA29774B1/fr unknown
- 2008-03-11 CR CR9807A patent/CR9807A/es not_active Application Discontinuation
- 2008-03-12 NO NO20081314A patent/NO20081314L/no not_active Application Discontinuation
-
2012
- 2012-03-28 US US13/432,359 patent/US20120196910A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2620090A1 (fr) | 2007-03-01 |
| EP1917013A1 (fr) | 2008-05-07 |
| EA016084B1 (ru) | 2012-02-28 |
| CR9807A (es) | 2008-07-29 |
| NO20081314L (no) | 2008-03-17 |
| ATE500826T1 (de) | 2011-03-15 |
| GB0517193D0 (en) | 2005-09-28 |
| CN101291669A (zh) | 2008-10-22 |
| ZA200801352B (en) | 2009-01-28 |
| IL189435A0 (en) | 2008-08-07 |
| US20120196910A1 (en) | 2012-08-02 |
| JP5166267B2 (ja) | 2013-03-21 |
| KR20080040022A (ko) | 2008-05-07 |
| ES2361933T3 (es) | 2011-06-24 |
| BRPI0614929A2 (pt) | 2011-04-19 |
| MX2008002564A (es) | 2008-03-18 |
| DE602006020589D1 (de) | 2011-04-21 |
| CN101291669B (zh) | 2012-09-26 |
| EA200800655A1 (ru) | 2008-08-29 |
| US20090036461A1 (en) | 2009-02-05 |
| AU2006284077A1 (en) | 2007-03-01 |
| JP2009506989A (ja) | 2009-02-19 |
| EP1917013B1 (fr) | 2011-03-09 |
| AU2006284077B2 (en) | 2012-05-17 |
| KR101363090B1 (ko) | 2014-02-13 |
| WO2007022980A1 (fr) | 2007-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29774B1 (fr) | Utilisation de derives azabicyclo | |
| BRPI0413234A (pt) | derivados de imidazola bicìclica contra flaviviridae | |
| EP2546246A3 (fr) | Composés et procédés pour le traitement et/ou la prévention dýinfections par flavivirus | |
| GEAP202415883A (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| EP2041159B8 (fr) | Composes macrocycliques en tant qu'agents antiviraux | |
| NO20090739L (no) | Kjemiske forbindelser | |
| MXPA05009015A (es) | Nuevos derivados de bencimidazol e imidazo-piridina y su utilizacion como medicamentos. | |
| PT1940839E (pt) | Inibidores de piridopirimidinona pi3k alfa | |
| TW200700406A (en) | Novel thiophene derivatives | |
| TW200801006A (en) | Fused bicyclic mTOR inhibitors | |
| TW200716591A (en) | Novel thiophene derivatives | |
| ES2422557T3 (es) | Compuestos y composiciones como moduladores de la ruta Hedgehog | |
| EA200870193A1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение | |
| TW200708511A (en) | Novel thiophene derivatives | |
| TW200716552A (en) | Novel thiophene derivatives | |
| EA200300829A1 (ru) | Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6 | |
| GEP20094727B (en) | Oxyindole derivatives as 5ht4 receptor agonists | |
| EA200970067A1 (ru) | Агонисты ep2 | |
| TW200738670A (en) | Novel thiophene derivatives | |
| WO2010047737A3 (fr) | Composés indoliniques antimicrobiens pour le traitement d'infections bactériennes | |
| HRP20090074T3 (en) | 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses | |
| IL191751A0 (en) | Pyrrolo[2,3-c]pyridine derivatives | |
| EA201300617A1 (ru) | β-ЛАКТАМОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-ЛАКТАМАЗЫ И ИХ ПРИМЕНЕНИЕ | |
| EA201290229A1 (ru) | Производные спиролактама и их применение | |
| JO2999B1 (ar) | مركب ثلاثي حلقي و استخدامه الدوائي |